Safety and antibody response to the first dose of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine in persons with HIV.

ABSTRACT: In this study of 12 people with HIV (PWH) who received the first dose of SARS-CoV-2 mRNA vaccination, anti-SARS-CoV-2 receptor-binding domain antibodies were detectable in all participants; lower antibody levels were seen in those with lower CD4+ counts, and vaccine reactions were generally mild.

SUBMITTER: Ruddy JA 

PROVIDER: S-EPMC10323866 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature